CVS Health Corporation (CVS)
CVS Health: Big 2025 Momentum, Strong Growth Ahead, Shares Underpriced
CVS Health has shown impressive year-to-date performance, driven by strong Q1 results and strategic shifts in its business model. I reiterate a buy rating on CVS due to its low valuation, mixed technicals, and promising earnings growth prospects. Key catalysts include improved performance in Healthcare Benefits, higher star ratings in Medicare Advantage, and strategic exits from less profitable areas.
CVS Health: Firing On All Cylinders, Thanks To The Promising Reversal
CVS' turnaround may be here, given the seemingly stabilizing medical cost trends as similarly reported by its peers, with it triggering the moderating Medical Benefit Ratio. This is despite the stable enrollments and the higher utilization, thanks to its improved Medicare Advantage star ratings and the growth in its commercial-fee businesses. We are likely to see CVS' Health Care Benefits segment report sequential improvements after the exit from the Affordable Care Act [ACA] plans from 2026 onwards as well.
What Makes CVS Health (CVS) a New Buy Stock
CVS Health (CVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think CVS Health (CVS) Is a Good Investment: Is It?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now?
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CVS Health (CVS) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Stocks in the S&P 500 Index Have Done the Unthinkable and Rocketed at Least 45% This Year Despite Trump's Tariffs
President Donald Trump's first 100 days proved tumultuous for the stock market. Trump instituted tariffs in his bid to bring more manufacturing jobs back to the U.S. and shake up global trade.
CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone
Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly's obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to CVS's exclusion, creating a temporary mispricing in Lilly's stock, presenting a potential buying opportunity. Despite CVS's exclusion, Zepbound still has broad market access through other PBMs and regional health plans, ensuring continued sales growth.
CVS Health: Why I'm Not Buying The Post-Earnings Share Buoyancy
CVS Health Corporation's Q1 2025 earnings show strong growth, with revenues up 7% YoY and adjusted EPS up 72%, but caution is advised for the long-term outlook. Despite positive quarterly results, CVS downgraded its full-year 2025 revenue guidance and faces ongoing challenges in its Medicare Advantage business. CVS is addressing issues in its Health Care Benefits division by terminating unprofitable contracts and improving star ratings, but risks remain high.
CVS Health (CVS) Q1 2025 Earnings Call Transcript
CVS Health Corporation (NYSE:CVS ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants David Joyner - President, Chief Executive Officer Tom Cowhey - Executive Vice President, Chief Financial Officer Prem Shah - Group President, CVS Health Steve Nelson - President, Aetna Larry McGrath - Chief Strategy Officer, Investor Relations Conference Call Participants Justin Lake - Wolfe Research Lisa Gill - JP Morgan Stephen Baxter - Wells Fargo Elizabeth Anderson - Evercore ISI Andrew Mok - Barclays Michael Cherny - Leerink Partners Charles Rhyee - TD Cowen Ann Hynes - Mizuho Securities Operator Good morning and thank you all for attending the CVS Health first Q1 2025 earnings call. My name is Bricka and I'll be your moderator for today.
CVS Health raises full-year profit outlook as Q1 earnings top estimates
CVS Health Corp (NYSE:CVS) shares rose after the pharmacy chain raised its full-year profit guidance and delivered strong financial results for the first quarter. The company now expects 2025 adjusted earnings per share (EPS) in the range of $6 to $6.20, up from its earlier guidance of $5.75 to $6.
